Unveiling Haloperidol's Impact: A Case Report on Induced Parkinsonism and Extrapyramidal Symptoms

Strong antipsychotic haloperidol is effective in treating delusions and hallucinations, but because of its strong antipsychotic properties, there is an increased extrapyramidal risk symptoms (EPS). We present the EPS case of a 39-year-old male who developed a delusional illness four weeks after injectable haloperidol treatment. Inj. promethazine (phenergan) 25 mg over a week was used to treat symptoms such as diminished movement and muscle stiffness. Frequent medical examinations are essential to halting the course of adverse events and improving both the financial and medical results. Accurate diagnosis, medication cessation, risk factor reduction, and supportive care are all part of primary management. Taking into account the EPS propensity of first-generation antipsychotics, some patient characteristics may indicate that second-generation medicines are better. The goal of this strategy is to minimize the EPS burden while optimizing efficacy.